Whalesbook
Margin Pressure Hits Profits Despite Revenue Growth
Ab ye jo profit gira hai na, uska reason hai margins ka kam hona. Pichhle saal jab 28% margin tha, woh ab 26.6% ho gaya hai. Iska matlab hai ki operational costs badh gayi hain, jisse company ka profit kam ho raha hai. Aur bhai sabse important baat, company ka P/E ratio bhi kaafi high hai, lagbhag 43.94x se 46.00x, jabki industry ka average toh sirf 27.64x hai. Ye high valuation tabhi justify hota hai jab profit growth acchi ho. Isi chinta ke karan stock 1.7% gir gaya, closing price ₹1,374.00 raha.
Valuation Concerns and Competitive Landscape
Market mein competitors ko dekho toh Metropolis Healthcare ka P/E 55x se 71x tak hai, lekin unka revenue aur profit growth Dr. Lal se kam hai. Toh Dr. Lal achha perform toh kar raha hai, par badhti costs ke beech ye premium valuation maintain karna mushkil ho sakta hai. Indian diagnostic market toh 2030 tak USD 34.68 billion tak jaane wala hai, jo 10.90% CAGR hai. Lekin bhai, energy costs aur supply chain issues jaise problems bhi aa rahi hain.
Margin Erosion and Leverage Risks
Company par debt bhi hai, Debt-to-Equity ratio 7.13 hai. Interest coverage ratio 25.69 hai, toh filhaal toh tension nahi hai, par agar profit aur gira toh problem ho sakti hai. Ye margin squeeze agar long-term raha toh earnings par impact padega. ₹4 ka dividend diya hai, par cost issues solve nahi hue. Sector mein technology aur investment ki bhi requirement hai, jo margins par pressure dal sakti hai.
Analyst Ratings and Future Outlook
Analysts ka view filhaal mixed hai. Kuch log 'Buy' rating de rahe hain, jaise Citi ne target ₹1,650 kiya hai, aur average target toh ₹1,719.54 hai. Lekin bhai, Goldman Sachs jaise log 'Sell' rating de rahe hain aur target ₹1,275 rakha hai. Management ka kehna hai ki revenue 11-12% badhega aur margins stable rahenge. Dekhna padega ki badhti costs ke beech yeh goals poore hote hain ya nahi, aur investors ka confidence bana rehta hai ya nahi.